Loudon Investment Management LLC Buys New Shares in MiMedx Group, Inc. (NASDAQ:MDXG)

Loudon Investment Management LLC bought a new stake in MiMedx Group, Inc. (NASDAQ:MDXG) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 12,000 shares of the company’s stock, valued at approximately $105,000.

Several other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of MiMedx Group by 4.1% in the third quarter. Vanguard Group Inc. now owns 6,437,155 shares of the company’s stock valued at $46,927,000 after buying an additional 250,812 shares during the period. Cannell Capital LLC raised its position in MiMedx Group by 106.7% in the third quarter. Cannell Capital LLC now owns 2,273,762 shares of the company’s stock worth $16,576,000 after purchasing an additional 1,173,506 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in MiMedx Group by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,076,509 shares of the company’s stock worth $7,848,000 after purchasing an additional 85,792 shares in the last quarter. EAM Investors LLC raised its position in MiMedx Group by 20.9% in the third quarter. EAM Investors LLC now owns 664,213 shares of the company’s stock worth $4,842,000 after purchasing an additional 114,880 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its position in MiMedx Group by 1,577.5% in the fourth quarter. Russell Investments Group Ltd. now owns 525,059 shares of the company’s stock worth $4,605,000 after purchasing an additional 493,759 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 price target on shares of MiMedx Group in a research report on Wednesday. Mizuho increased their price target on shares of MiMedx Group from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Finally, Lake Street Capital assumed coverage on shares of MiMedx Group in a research report on Thursday, March 7th. They issued a “buy” rating and a $12.00 price target for the company. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $12.25.

MiMedx Group Price Performance

Shares of MDXG stock traded up $0.19 during trading hours on Thursday, hitting $7.50. 1,066,184 shares of the company’s stock were exchanged, compared to its average volume of 796,332. The stock’s 50-day moving average is $7.38 and its 200-day moving average is $7.56. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.57 and a quick ratio of 3.11. MiMedx Group, Inc. has a 52 week low of $4.47 and a 52 week high of $9.27. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of 17.14 and a beta of 1.44.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). MiMedx Group had a net margin of 18.63% and a return on equity of 64.61%. The company had revenue of $86.83 million during the quarter, compared to analyst estimates of $85.58 million. As a group, research analysts forecast that MiMedx Group, Inc. will post 0.33 EPS for the current year.

Insiders Place Their Bets

In other MiMedx Group news, CAO William Frank Iv Hulse sold 20,381 shares of the business’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total value of $162,028.95. Following the completion of the transaction, the chief accounting officer now directly owns 479,959 shares of the company’s stock, valued at $3,815,674.05. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CAO William Frank Iv Hulse sold 20,381 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total transaction of $162,028.95. Following the completion of the sale, the chief accounting officer now directly owns 479,959 shares of the company’s stock, valued at $3,815,674.05. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Ricci S. Whitlow sold 15,493 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $8.07, for a total transaction of $125,028.51. Following the sale, the chief operating officer now directly owns 416,321 shares of the company’s stock, valued at $3,359,710.47. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,145 shares of company stock valued at $409,378. Insiders own 19.90% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.